Navigation Links
Bionovo Announces Second Quarter 2009 Highlights and Financial Results
Date:8/10/2009

EMERYVILLE, Calif., Aug. 10 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced second quarter highlights and financial results for the three months ended June 30, 2009.

Company Highlights

    -- Further results from the phase 1B clinical trial of Bezielle (BZL101)
       in 27 patients with metastatic breast cancer showed Bezielle to be
       safe and well-tolerated with encouraging evidence of clinical activity
       in a heavily pretreated patient population - most importantly
       including:

       -- 31% had stable disease for more than 90 days;
       -- 13% had stable disease for more than 180 days;
       -- three patients had objective tumor regression;
       -- one patient had objective tumor regression while on Bezielle
          therapy for 449 days and continues to be stable off of study
          medication for over 600 days;
       -- a second patient continues to be stable for 832 days and has not
          started any new anticancer treatment;
       -- a third patient was stable without any new anticancer therapy for
          591 days;
       -- there were no deaths or serious adverse events that were attributed
          to Bezielle (BZL101); and
       -- the most common side effects associated with Bezielle (BZL101) were
          minor and gastrointestinal in nature.


       These results provide further evidence that Bezielle (BZL101) may
       provide an important option for women suffering from advanced breast
       cancer, an extremely difficult to treat subset of the breast cancer
       population.

    -- On the SERM platform, a peer-reviewed study published in the journal
       "Public Library of Science One" found that when comparing the gene
       expression induced by ERb compounds to that induced by est
'/>"/>
SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
2. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
3. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
4. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
5. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
8. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
9. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
10. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
11. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)...   3D Systems   (NYSE: DDD ) ... , a new robotic surgery skills and procedural training simulator, ... ERUS exhibition in Amsterdam, The Netherlands ... minimally invasive surgery represents a growing portion of overall surgical ... for robotic surgery has increased, and it is expected that ...
(Date:9/18/2014)...  Neurotrope, Inc. (OTCQB: NTRP) today announced the appointment ... the Company,s Board of Directors, effective September 12, 2014. ... the Board of seven members. Dr. Altstiel will also ... and a member of the Audit and Compensation Committees ... Scientific Advisory Board, a position he has held since ...
(Date:9/18/2014)... , Sept. 18, 2014 Australian biomarker discovery ... US trial of its MiStat™ prostate cancer screening test, ... regulatory approval upon completion. Minomic,s proprietary MiStat™ ... presence of a proprietary biomarker known as the MIL-38 ... prostate cancer cells. Researchers at 11 ...
Breaking Medicine Technology:3D Systems Introduces New Simbionix Robotics Training Platform 23D Systems Introduces New Simbionix Robotics Training Platform 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 2Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 4Minomic Launches US Pilot Study of MiStat(TM) Novel Prostate Cancer Screening Technology 2
... EATONTOWN, N.J. , Jan. 14 Osteotech, Inc. (Nasdaq: ... products for regenerative healing, today reported preliminary unaudited revenue for the ... $24.6 million for the same period in 2008.  During ... revenue from sales of its new innovative products all currently in ...
... and NORTH BRUNSWICK, N.J. , Jan. 14 ... that they have achieved the initial milestone of a research ... vitro test for potential allergic reactions to substances that could ... "Allergy Test on a Chip™," is intended to comprise a ...
Cached Medicine Technology:Osteotech Announces Preliminary Fourth Quarter 2009 Revenue 2Osteotech Announces Preliminary Fourth Quarter 2009 Revenue 3Osteotech Announces Preliminary Fourth Quarter 2009 Revenue 4L'OREAL and Hurel Corporation Announce R&D Collaboration to Develop a Non-Animal Alternative, Microfluidic Biochip 2L'OREAL and Hurel Corporation Announce R&D Collaboration to Develop a Non-Animal Alternative, Microfluidic Biochip 3
(Date:9/18/2014)... is good for you. But new research from University ... added benefit for cancer patients undergoing chemotherapy. , Their ... that combining exercise with chemotherapy shrunk tumors more than ... in the School of Nursing and director of the ... senior author on the study, which appears in the ...
(Date:9/18/2014)... September 18, 2014 TayganPoint Consulting ... today that President and co-founder John Cassimatis was ... Award Winners for 2014, recognizing the region’s top ... an emerging executive of the year. , The ... life sciences that continue to shape the medical ...
(Date:9/18/2014)... September 18, 2014 Ben Quirk, CEO ... Ormond, Jr. Leadership Award by the Savannah Science Seminar ... and wellness throughout the nation and especially in Savannah. ... award,” said Ben. “The Savannah Science Seminar is an ... and multiple generations have gone through the program,” he ...
(Date:9/18/2014)... new method to study Ebola virus in wildlife. Video ... (WCS)-led research, published today in the journal PLOS ... samples from wild great apes to identify populations likely ... a new tool for performing large, population-scale field assessments ... studied and improve our understanding of the virus, distribution ...
(Date:9/18/2014)... The National Institutes of Health (NIH) recently awarded the ... grant to the Los Angeles Biomedical Research Institute (LA ... a vaccine to protect patients from the healthcare-related infections, ... (MRSA). , The National Institute of Allergy and ... to LA BioMed infectious disease specialists John E. Edwards, ...
Breaking Medicine News(10 mins):Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2
... ITASCA, Ill., March 20 Arthur J. ... Healthcare Risk Solutions, LLC,headquartered in Fort Washington, ... Founded in 2002, Healthcare Risk Solutions, ... professional liability insurance,products, associated risk mitigation consulting ...
... PRGO ; TASE) today announced that the ... Jersey has denied Connetics Corporation,s motion,for a preliminary ... generic equivalent to Connetics, Olux(R) Foam and has,lifted ... launching,the product. The Court also denied Perrigo,s motion ...
... emotional well-being, study suggests , , THURSDAY, March 20 (HealthDay ... health of the husband -- as either patient or ... of mind, new research suggests. , The finding suggests ... his wife,s experience of psychological distress more so than ...
... WASHINGTON, March 20 Veterans in seven,additional states ... Department of Veterans Affairs (VA) plan to open 14 ... James B. Peake today,announced that VA will establish new ... "VA is dedicated to providing the best in ...
... was a rainy,Saturday, nothing could dampen the spirits ... Free Families (DCTFF) hosted a special evening at,Saturday,s ... over 100 D.C.,residents who have quit smoking using ... Health Care, Inc., (Photo: http://www.newscom.com/cgi-bin/prnh/20080320/NETH063 ...
... halve by 2015 the number of people without toilet access ... every dollar spent installing toilets in developing countries, there would ... according to a UN report released today. , The UN ... 2015 the number of people worldwide who don,t have access ...
Cached Medicine News:Health News:Perrigo Company Announces Launch of Clobetasol Propionate Foam 2Health News:Perrigo Company Announces Launch of Clobetasol Propionate Foam 3Health News:Cancer Poses Challenges for Husbands' Frame of Mind 2Health News:Cancer Poses Challenges for Husbands' Frame of Mind 3Health News:VA to Open 14 New Clinics in Seven States 2Health News:Quitters Honored at Wizards' DC Tobacco Free Family Night 2Health News:Cleaning Up the World's Sanitation 2
Used to negotiate tortuous vessels....
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
... The CYPHER Sirolimus-eluting Coronary Stent ... drug, called "sirolimus", a controlled-release ... delivery platform. Upon placement, sirolimus ... and impedes the process of ...
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
Medicine Products: